查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800149

全球再生医学市场：2025年至2030年预测

Global Regenerative Drugs Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2030 年再生医学市场规模将从 145.4 亿美元成长至 290.63 亿美元，复合年增长率为 14.86%。

再生医学是医疗保健领域的创新方法，专注于修復、替换和再生受损的组织和器官，以恢復正常的身体功能。这些药物透过修復无法自然修復的组织来促进再生，其过程包括再生（将健康细胞和组织输送到患病或受损部位）和替换（使用捐赠者的健康细胞、组织或器官替代受损组织）。再生医学的一项关键进展是能够利用患者自身的细胞在实验室中培育器官，从而有可能降低移植排斥的风险并解决器官短缺的难题。这一创新领域可望彻底改变各医学学科的治疗方法。

市场按类型、材料、应用、最终用户和地区细分。按类型划分，药物包括合成药物、生物衍生药物和基因衍生药物，反映了组织修復和再生的多种方法。这些疗程中使用的材料包括生物分解性聚合物、支架、水凝胶、胶原胶原蛋白、基因改造材料和纤维母细胞，每种材料均根据特定的再生需求量身定制。应用涵盖心血管、肿瘤、皮肤、肌肉骨骼、创伤治疗、眼科和神经内科等关键领域，凸显了再生医学的广泛治疗潜力。最终用户包括医院、生物医学实验室和研究中心，推动这些治疗方法的创新和应用。

从区域来看，市场细分为北美、南美、欧洲、中东和亚太地区。欧洲，尤其是德国、法国和英国，是再生医学的主要枢纽，其强大的商业部门专注于细胞疗法。这些治疗方法通常利用患者自身细胞或来自非亲缘捐赠者的异体细胞，以满足多样化的临床需求并推广个人化医疗。

再生医学市场竞争激烈，百特国际、史赛克公司、美敦力公司、CryoLife公司和Organogenic公司（Advanced BioHealing）等主要企业引领着产业发展。这些公司透过研发推动创新，专注于开发新型治疗方法和可扩展的解决方案，以满足日益增长的需求。市场成长的动力源于对再生技术投资的不断增加，以及对慢性和退化性疾病有效治疗方案日益增长的需求。

总而言之，在细胞治疗方法和器官再生技术的推动下，再生医学市场预计将大幅扩张。再生医学在医疗领域的广泛应用，加上其在欧洲的强劲表现和全球范围内日益增长的普及，凸显了其改变医疗保健行业的潜力。随着主要企业不断创新和拓展产品组合，再生医学有望在满足未满足的医疗需求和改善患者预后方面发挥关键作用。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力来提供策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业来说，都是有益且具有成本效益的。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2020 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（尤其是趋势）、财务资讯和关键发展

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章 全球再生医学市场（按技术）

  • 介绍
  • 干细胞疗法
  • 基因治疗
  • 组织工程
  • 小分子和生技药品

第六章全球再生医学药物市场（按材料）

  • 介绍
  • 生物分解性合成聚合物
  • 鹰架
  • 水凝胶和胶原蛋白
  • 基因改造
  • 纤维母细胞

第七章全球再生医学药物市场（按应用）

  • 介绍
  • 心血管系统
  • 肿瘤学
  • 皮肤科
  • 肌肉骨骼
  • 创伤治疗
  • 眼科
  • 神经病学
  • 其他的

第八章全球再生医学市场（按最终用户）

  • 介绍
  • 医院
  • 生物医学研究所
  • 研究中心

第九章全球再生医学市场（按地区）

  • 介绍
  • 北美洲
    • 依技术
    • 按材质
    • 按用途
    • 按最终用户
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依技术
    • 按材质
    • 按用途
    • 按最终用户
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 依技术
    • 按材质
    • 按用途
    • 按最终用户
    • 按国家
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 依技术
    • 按材质
    • 按用途
    • 按最终用户
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 依技术
    • 按材质
    • 按用途
    • 按最终用户
    • 按国家
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第十章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • Organogenesis Holdings Inc.
  • MiMedx Group, Inc.
  • Vericel Corporation
  • Smith & Nephew plc
  • Integra LifeSciences Holdings Corporation
  • Stryker Corporation
  • Medtronic plc
  • Baxter International Inc.
  • Orthofix Medical Inc.
  • RTI Surgical

第十二章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061611188

The Global Regenerative Drugs Market is expected to grow from USD 14.540 billion to USD 29.063 billion in 2030, at a CAGR of 14.86%.

Regenerative drugs represent a transformative approach in healthcare, focusing on repairing, replacing, or regenerating damaged tissues and organs to restore normal bodily functions. These medicines facilitate rejuvenation by healing tissues that cannot naturally recover, using processes such as regeneration, where healthy cells or tissues are delivered to diseased or damaged areas, or replacement, where healthy cells, tissues, or organs from donors are used to substitute damaged ones. A significant advancement in regenerative medicine is the potential to grow organs in laboratory settings using a patient's own cells, reducing the risk of transplant rejection and addressing organ shortage challenges. This innovative field holds promise for revolutionizing treatment across various medical domains.

The global regenerative drugs market is segmented by type, materials, application, end-users, and geography. By type, the market includes synthetic, biologically derived, and genetically derived drugs, reflecting diverse approaches to tissue repair and regeneration. Materials used in these therapies encompass biodegradable synthetic polymers, scaffolds, hydrogel and collagen, transgenic materials, and fibroblasts, each tailored to specific regenerative needs. Applications span critical areas such as cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others, highlighting the broad therapeutic potential of regenerative drugs. End-users include hospitals, biomedical laboratories, and research centers, which drive innovation and application of these therapies.

Geographically, the market is divided into North America, South America, Europe, the Middle East, and the Asia-Pacific region. Europe, particularly Germany, France, and the UK, serves as a major hub for regenerative medicine, with a strong commercial sector focused on cell-based therapies. These therapies often utilize autologous cells from the patient or allogeneic cells from unrelated donors, catering to diverse clinical needs and advancing personalized medicine.

The regenerative drugs market is highly competitive, with key players such as Baxter International, Stryker Corporation, Medtronic plc, CryoLife, Inc., and Organogenesis, Inc. (Advanced BioHealing) leading the industry. These companies are driving innovation through research and development, focusing on novel therapies and scalable solutions to meet growing demand. The market's growth is fueled by increasing investment in regenerative technologies and a rising need for effective treatments for chronic and degenerative diseases.

In conclusion, the regenerative drugs market is poised for significant expansion, driven by advancements in cell-based therapies and organ regeneration techniques. Its broad applications across medical fields, coupled with a strong presence in Europe and growing global adoption, underscore its potential to transform healthcare. As key players continue to innovate and expand their portfolios, regenerative medicines will play a pivotal role in addressing unmet medical needs and improving patient outcomes.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Technology

  • Stem cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Small Molecules & Biologics

By Materials

  • Biodegradable Synthetic Polymers
  • Scaffold
  • Hydrogel & Collagen
  • Transgenic
  • Fibroblasts

By Applications

  • Cardiovascular
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Wound Healing
  • Ophthalmology
  • Neurology
  • Others

By End-Users

  • Hospitals
  • Biomedical Laboratories
  • Research Centers

By Geography

  • North America
  • South America
  • Europe
  • Middle East and Africa
  • Asia Pacific

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL REGENERATIVE DRUGS MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Stem cell Therapy
  • 5.3. Gene Therapy
  • 5.4. Tissue Engineering
  • 5.5. Small Molecules & Biologics

6. GLOBAL REGENERATIVE DRUGS MARKET BY MATERIALS

  • 6.1. Introduction
  • 6.2. Biodegradable Synthetic Polymers
  • 6.3. Scaffold
  • 6.4. Hydrogel & Collagen
  • 6.5. Transgenic
  • 6.6. Fibroblasts

7. GLOBAL REGENERATIVE DRUGS MARKET BY APPLICATIONS

  • 7.1. Introduction
  • 7.2. Cardiovascular
  • 7.3. Oncology
  • 7.4. Dermatology
  • 7.5. Musculoskeletal
  • 7.6. Wound Healing
  • 7.7. Ophthalmology
  • 7.8. Neurology
  • 7.9. Others

8. GLOBAL REGENERATIVE DRUGS MARKET BY END-USERS

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Biomedical Laboratories
  • 8.4. Research Centers

9. GLOBAL REGENERATIVE DRUGS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Technology
    • 9.2.2. By Materials
    • 9.2.3. By Applications
    • 9.2.4. By End-Users
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Technology
    • 9.3.2. By Materials
    • 9.3.3. By Applications
    • 9.3.4. By End-Users
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Technology
    • 9.4.2. By Materials
    • 9.4.3. By Applications
    • 9.4.4. By End-Users
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Technology
    • 9.5.2. By Materials
    • 9.5.3. By Applications
    • 9.5.4. By End-Users
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Technology
    • 9.6.2. By Materials
    • 9.6.3. By Applications
    • 9.6.4. By End-Users
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. Japan
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Organogenesis Holdings Inc.
  • 11.2. MiMedx Group, Inc.
  • 11.3. Vericel Corporation
  • 11.4. Smith & Nephew plc
  • 11.5. Integra LifeSciences Holdings Corporation
  • 11.6. Stryker Corporation
  • 11.7. Medtronic plc
  • 11.8. Baxter International Inc.
  • 11.9. Orthofix Medical Inc.
  • 11.10. RTI Surgical

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations